Эффективность и безопасность тирзепатида в лечении ожирения и ассоциированных с ним коморбидных состояний

Цель настоящей публикации – продемонстрировать эффективность применения тирзепатида у пациента с ожирением и ассоциированными коморбидными состояниями в условиях реальной клинической практики. Представлено клиническое наблюдение пациента 36 лет с ожирением II степени, артериальной гипертензией, нарушенной толерантностью к глюкозе, гиперлипидемией, гиперурикемией и метаболически ассоциированной жировой болезнью печени. Исходно масса тела пациента составляла 126 кг, индекс массы тела – 38 кг/м2, окружность талии – 117 см. Пациенту были рекомендованы модификация образа жизни и терапия тирзепатидом с постепенной титрацией дозы до 12,5 мг 1 раз в неделю. Через 15 мес. терапии масса тела снизилась до 91 кг (-27,8%), индекс массы тела – до 27,8 кг/м2, окружность талии – до 94 см. Отмечено улучшение композиционного состава тела в виде уменьшения массы жировой ткани при сохранении мышечного компонента. На фоне лечения достигнута нормализация показателей углеводного обмена, липидного профиля, уровня мочевой кислоты и артериального давления. По данным эхокардиографии отмечалось уменьшение толщины эпикардиальной жировой ткани. Клинически значимых нежелательных явлений на протяжении периода наблюдения зарегистрировано не было. Тирзепатид является перспективным терапевтическим инструментом для лечения ожирения у пациентов с кардиометаболическими нарушениями. В условиях реальной практики применение препарата позволяет достигать выраженного снижения массы тела, сопровождающегося благоприятной динамикой показателей углеводного, липидного и пуринового обмена, а также снижением сердечно-сосудистого риска. Особый интерес представляет возможность уменьшения жирового компонента массы тела при сохранении мышечной ткани. Хорошая переносимость терапии и отсутствие значимых нежелательных явлений подтверждают высокий терапевтический потенциал тирзепатида у пациентов с осложненным ожирением и коморбидной патологией.

1. Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221–262. https://doi.org/10.1016/S2213-8587(24)00316-4.

2. Fitch AK, Bays HE. Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obes Pillars. 2022;1:100004. https://doi.org/10.1016/j.obpill.2021.100004.

3. Дедов ИИ, Мокрышева НГ, Мельниченко ГА, Трошина ЕА, Мазурина НВ, Ершова ЕВ и др. Клинические рекомендации «Ожирение» Минздрава России. Версия 2024 года. Вестник репродуктивного здоровья. 2025;4(2):14–30. https://doi.org/10.14341/brh12763.

4. Баланова ЮА, Шальнова СА, Имаева АЭ, Куценко ВА, Капустина АВ, Муромцева ГА и др. Ожирение в российской популяции: вклад в выживаемость и возникновение сердечно-сосудистых событий. Данные исследований ЭССЕ-РФ и ЭССЕ-РФ2. Кардиоваскулярная терапия и профилактика. 2025;24(6):4336. https://doi.org/10.15829/1728-8800-2025-4336.

5. Yanovski SZ, Yanovski JA. Approach to Obesity Treatment in Primary Care: A Review. JAMA Intern Med. 2024;184(7):818–829. https://doi.org/10.1001/jamainternmed.2023.8526.

6. Sumithran P, Proietto J. The defence of body weight: a physiological basis for weight regain after weight loss. Clin Sci. 2013;124(4):231–241. https://doi.org/10.1042/CS20120223.

7. Nadolsky K, Garvey WT, Agarwal M, Bonnecaze A, Burguera B, Chaplin MD et al. American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity--Based Chronic Disease – 2025 Update. Endocr Pract. 2025;31(11):1351–1394. https://doi.org/10.1016/j.eprac.2025.07.017.

8. Jastreboff AM, le Roux CW, Stefanski A, Aronne LG, Halpern B, Wharton S et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025;392(10):958–971. https://doi.org/10.1056/NEJMoa2410819.

9. Saha B, Kamalumpundi V, Codipilly DC. GLP1 and GIP Receptor Agonists: Effects on the Gastrointestinal Tract and Management Strategies for Primary Care Physicians. Mayo Clin Proc. 2025;100(12):2228–2236. https://doi.org/10.1016/j.mayocp.2025.09.017.

10. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF. Lingvay I et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. https://doi.org/10.1056/nejmoa2032183.

11. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205–216. https://doi.org/10.1056/nejmoa2206038.

12. Forzano I, Varzideh F, Avvisato R, Jankauskas SS, Mone P, Santulli G. Tirzepatide: A Systematic Update. Int J Mol Sci. 2022;23(23):14631. https://doi.org/10.3390/ijms232314631.

13. Hamza M, Papamargaritis D, Davies MJ. Tirzepatide for overweight and obesity management. Expert Opin Pharmacother. 2025;26(1):31–49. https://doi.org/10.1080/14656566.2024.2436595.

14. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon LB, Valderas EG et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26–36. https://doi.org/10.1056/NEJMoa2416394.

15. Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143–155. https://doi.org/10.1016/S0140-6736(21)01324-6.

16. Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503–515. https://doi.org/10.1056/NEJMoa2107519.

17. Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583–598. https://doi.org/10.1016/S0140-6736(21)01443-4.

18. Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811–1824. https://doi.org/10.1016/S0140-6736(21)02188-7.

19. Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodríguez Á. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327(6):534–545. https://doi.org/10.1001/jama.2022.0078.

20. Rosenstock J, Frías JP, Rodbard HW, Tofé S, Sears E, Huh R et al. Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial. JAMA. 2023;330(17):1631–1640. https://doi.org/10.1001/jama.2023.20294.

21. Garvey WT, Frias JP, Jastreboff AM, le Roux С, Sattar N, Aizenberg D et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613–626. https://doi.org/10.1016/S0140-6736(23)01200-X.

22. Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2024;30(6):1784. https://doi.org/10.1038/s41591-024-02883-1.

23. Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48. https://doi.org/10.1001/jama.2023.24945.

24. Sinha R, Papamargaritis D, Sargeant JA, Davies MJ. Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management. J Obes Metab Syndr. 2023;32(1):25–45. https://doi.org/10.7570/jomes22067.

25. Sattar N, García-Pérez L-E, Rodríguez A, Kapoor R, Stefanski A, Hankosky ER. Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence. Diabetes Obes Metab. 2025;27(10):5386–5392. https://doi.org/10.1111/dom.16549.

26. McGowan B, Ciudin A, Baker JL, Busetto L, Dicker D, Frühbeck G et al. Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO). Nat Med. 2025;31(10):3229–3232. https://doi.org/10.1038/s41591-025-03765-w.

27. Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M. Obesity Management in Adults: A Review. JAMA. 2023;330(20):2000–2015. https://doi.org/10.1001/jama.2023.19897.

28. Шестакова МВ, Башлыкова РО. Перспективы лечения сахарного диабета 2-го типа и ожирения: настоящее и будущее инкретинотерапии. Терапевтический архив. 2025;97(10):823–829. https://doi.org/10.26442/00403660.2025.10.203366.

29. Liu S, Hu J, Zhao C, Liu H, He C. Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis. Front Endocrinol. 2025;16:1513641. https://doi.org/10.3389/fendo.2025.1513641.

30. Koskinas KC, Van Craenenbroeck EM, Antoniades C, Blüher M, Gorter TM, Hanssen H et al. Obesity and cardiovascular disease: an ESC clinical consensus statement. Eur J Prev Cardiol. 2025;32(3):184–220. https://doi.org/10.1093/eurjpc/zwae279.

31. Krumholz HM, de Lemos JA, Sattar N, Linetzky B, Sharma Р, Mast CJ et al. Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial. Heart. 2024;110(19):1165–1171. https://doi.org/10.1136/heartjnl-2024-324170.

32. de Lemos JA, Linetzky B, le Roux CW, Laffin LJ, Vongpatanasin W, Fan L et al. Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m(2): SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy. Hypertension. 2024;81(4):e41–e43. https://doi.org/10.1161/HYPERTENSIONAHA.123.22022.

33. Kanbay M, Copur S, Siriopol D, Yildiz AB, Gaipov A, van Raalte DH, Tuttle KR. Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2023;25(12):3766–3778. https://doi.org/10.1111/dom.15272.

34. Carraro-Lacroix LR, Malnic G, Girardi ACC. Regulation of Na+ /H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Renal Physiol. 2009;297(6):F1647–F1655. https://doi.org/10.1152/ajprenal.00082.2009.

35. Cho YK, La Lee Y, Jung CH. The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist. J Lipid Atheroscler. 2023;12(3):213–222. https://doi.org/10.12997/jla.2023.12.3.213.

36. Linetzky B, See SK, Zhang X, Stefanski А, Wilson J, Ruotolo G. Body weight reduction-associated and -unassociated changes in lipid profile in people with obesity, with or without T2D, treated with tirzepatide: post-hoc analysis of SURMOUNT-1 and SURMOUNT-2. Circulation. 2024;150(Suppl. 1):4141358. https://doi.org/10.1161/circ.150.suppl_1.4141358.

37. Angelopoulos N, Livadas S, Androulakis I, Petkova, V, Rizoulis A, Boniakos A et al. Short-term effects of low-dose tirzepatide on lipid profile, glucose homeostasis and hepatic steatosis index in adults with obesity, but without diabetes mellitus: a prospective observational study. J Diabetes Complications. 2025;39(12):109181. https://doi.org/10.1016/j.jdiacomp.2025.109181.

38. Xie F, Zhang W. Effects of tirzepatide on lipid profiles in type 2 diabetes mellitus A meta-analysis. Clin Focus. 2025;40(12):1061–1067. https://doi.org/10.3969/j.issn.1004-583X.2025.12.001.

39. Mahar MU, Mahmud O, Ahmed S, Qureshi SA, Kakar WG, Fatima SS. The Effects of Tirzepatide on Lipid Profile: A Systematic Review and MetaAnalysis of Randomized Controlled Trials. J Obes Metab Syndr. 2024;33(4):348–359. https://doi.org/10.7570/jomes24008.

40. Feingold KR. Obesity and Dyslipidemia. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G et al. (eds.). Endotext. South Dartmouth (MA): MDText.com, Inc.; 2026. Available at: https://www.ncbi.nlm.nih.gov/books/NBK305895/.

41. Bu T, Sun Z, Pan Y, Deng X, Yuan G. Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism. Diabetes Metab J. 2024;48(3):354–372. https://doi.org/10.4093/dmj.2023.0277.

42. Sachs S, Götz A, Finan B, Feuchtinger А, DiMarchi RD, Döring Y et al. GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardiometabolic disease. Cardiovasc Diabetol. 2023;22(1):217. https://doi.org/10.1186/s12933-023-01940-2.

43. Wilson JM, Nikooienejad A, Robins DA, Roell WC, Riesmeyer JS, Haupt A et al. The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes Obes Metab. 2020;22(12):2451–2459. https://doi.org/10.1111/dom.14174.

44. Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10(6):393–406. https://doi.org/10.1016/S2213-8587(22)00070-5.

45. Sattar N, Scilletta S, Stefanski A, Wang H, Daly JW, Linetzky B. Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial. Ann Rheum Dis. 2026;85(3):558–565. https://doi.org/10.1016/j.ard.2025.10.009.

46. Mandal AK, Leask MP, Estiverne C, Choi HK, Merriman TR, Mount DB. Genetic and Physiological Effects of Insulin on Human Urate Homeostasis. Front Physiol. 2021;12:713710. https://doi.org/10.3389/fphys.2021.713710.

47. Xu L, Shi Y, Zhuang S, Liu N. Recent advances on uric acid transporters. Oncotarget. 2017;8(59):100852–100862. https://doi.org/10.18632/oncotarget.20135.

48. Tonneijck L, Muskiet MHA, Smits MM, Bjornstad P, Kramer MHH, Diamant M et al. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials. Diabetes Obes Metab. 2018;20(5):1235–1245. https://doi.org/10.1111/dom.13223.

49. Mather KJ, Coskun T, Pratt EJ, Milicevic Z, Weerakkody G, Thomas MK et al. Improvements in post-challenge lipid response following tirzepatide treatment in patients with type 2 diabetes. Diabetes Obes Metab. 2024;26(2):785–789. https://doi.org/10.1111/dom.15365.

50. Wilson JM, Lin Y, Luo MJ, Considine G, Cox АL, Bowsman LM et al. The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis. Diabetes Obes Metab. 2022;24(1):148–153. https://doi.org/10.1111/dom.14553.

51. Borlaug BA, Zile MR, Kramer CM, Baum SJ, Hurt K, Litwin SE et al. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nat Med. 2025;31(2):544–551. https://doi.org/10.1038/s41591-024-03374-z.

52. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol. 2022;19(9):593–606. https://doi.org/10.1038/s41569-022-00679-9.

53. Li C, Liu X, Adhikari BK, Chen L, Liu W, Wang Y, Zhang H. The role of epicardial adipose tissue dysfunction in cardiovascular diseases: an overview of pathophysiology, evaluation, and management. Front Endocrinol. 2023;14:1167952. https://doi.org/10.3389/fendo.2023.1167952.

54. Packer M. Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium. J Am Coll Cardiol. 2018;71(20):2360–2372. https://doi.org/10.1016/j.jacc.2018.03.509.

55. Wiszniewski K, Grudniewska A, Szabłowska-Gadomska I, Pilichowska-Paszkiet E, Zaborska B, Zgliczyński W et al. Epicardial Adipose Tissue – A Novel Therapeutic Target in Obesity Cardiomyopathy. Int J Mol Sci. 2025;26(16):7963. https://doi.org/10.3390/ijms26167963.

56. Dozio E, Vianello E, Malavazos AE, Tacchini L, Schmitz G, Iacobellis G, Corsi Romanelli MM. Epicardial adipose tissue GLP-1 receptor is associated with genes involved in fatty acid oxidation and white-to-brown fat differentiation: A target to modulate cardiovascular risk? Int J Cardiol. 2019;292:218–224. https://doi.org/10.1016/j.ijcard.2019.04.039.

57. Gustafsson B, Rovio SP, Ruohonen S, Kähönen NH, Kähönen M, Viikari JSA et al. Determinants of echocardiographic epicardial adipose tissue in a general middle aged population – The Cardiovascular Risk in Young Finns Study. Sci Rep. 2024;14(1):11982. https://doi.org/10.1038/s41598-024-61727-7.

58. Kramer CM, Borlaug BA, Zile MR, Ruff D, DiMaria JM, Menon V et al. Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy. J Am Coll Cardiol. 2025;85(7):699–706. https://doi.org/10.1016/j.jacc.2024.11.001.

59. Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427–437. https://doi.org/10.1056/NEJMoa2410027.

60. Malavazos AE, Iacobellis G, Dozio E, Basilico S, Di Vincenzo A, Dubini C et al. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies. Eur J Prev Cardiol. 2023;30(8):680–693. https://doi.org/10.1093/eurjpc/zwad050.